Pralsetinib and selpercatinib recommendations were based on multicenter, open label, multi-cohort clinical trials, ARROW, NCT03037385 [162] and LIBRETTO-001, NCT03157128, respectively, that investigated their efficacy in MTC patients with RET gene alterations. Here, RET is linked to medullary thyroid gland carcinoma.